Picolinic acid

Other Names

2-Carboxypyridine2-Picolinate2-Picolinic acid2-Pyridincarbonsäure2-Pyridinecarboxylic acid2-Pyridylcarboxylic acidAcide picoliqueAcide picolique [French]Acide pyridine-2-carboxyliquealpha-Picolinic acidalpha-Pyridinecarboxylic acidNSC 171NSC 21209o-Pyridinecarboxylic acidpicolic acidPicolinatePicolinsäurePicolonic acidPyridine-2-carboxylic acidPYRIDINE-ALPHA-CARBOXYLIC ACIDPyridine-carboxylique-2Pyridine-carboxylique-2 [French]pyridinecarboxylic acidPyridinecarboxylic acid-(2)pyridinoic acidpyridylcarboxylic acidα-Picolinic acidα-Pyridinecarboxylic acid

Synopsis

Picolinic Acid: A Comprehensive Reference

1. Identity and Chemical Characterization

1.1 Chemical Names and Structural Identity

Picolinic acid is a naturally occurring organic compound classified as a pyridinemonocarboxylic acid, featuring a carboxylic acid group attached to the 2-position of a pyridine ring, with the molecular formula C₆H₅NO₂ and a molecular weight of 123.11 g/mol. It is an isomer of nicotinic acid and isonicotinic acid, which have the carboxyl side chain at the 3- and 4-positions, respectively. The compound is known by several synonymous names, including pyridine-2-carboxylic acid, 2-pyridinecarboxylic acid, 2-picolinic acid, and its salts are collectively referred to as picolinates. Its CAS registry number is 98-98-6.

It appears as a white to off-white crystalline solid with a melting point of approximately 137–142 °C and high solubility in water (about 960 mg/mL at 20 °C).

1.2 Relationship to Nicotinic Acid

Nicotinic acid (pyridine-3-carboxylic acid) has a very similar structure to picolinic acid (pyridine-2-carboxylic acid). Nicotinic acid and picolinic acid form coordination complexes with monovalent, divalent, and trivalent metal ions and facilitate the absorption of these metals by transporting them across intestinal cells and into the bloodstream. Despite this structural similarity, the two compounds have distinct biochemical roles and pharmacological profiles.

1.3 Natural Biological Occurrence

As an endogenous metabolite derived from the kynurenine pathway of L-tryptophan catabolism, picolinic acid plays a key role in cellular processes, including zinc chelation and transport, which contribute to its immunomodulatory and anti-infective effects. Picolinic acid has been detected in a variety of biological mediums including cell culture supernatants, blood serum, cerebrospinal fluid (CSF), human milk, pancreatic juice, and intestinal homogenates.

1.4 Common Supplement Forms and Preparations

Salts of picolinic acid, such as chromium picolinate and zinc picolinate, have been widely used as dietary and animal feed supplements. Picolinic acid itself is also found in free-acid form and as a chelating ligand within multimetal mineral formulations. It exhibits diverse functionalities as a mineral chelator, metal cleaning agent, and bioactive compound with antimicrobial, antiviral, and antitumor activities. On a commercial scale, picolinic acid is produced by ammoxidation of 2-picoline followed by hydrolysis of the resulting nitrile. Conventional chemical synthesis of picolinic acid involves harsh reaction conditions and poses environmental concerns, prompting research into microbial biosynthesis routes.

2. Biosynthesis and Endogenous Metabolism

2.1 The Kynurenine Pathway

The kynurenine (KYN) pathway is a branch of the tryptophan metabolic cascade that is unique since it generates multiple neuroactive metabolites, including 3-hydroxykynurenine (3-HK), kynurenic acid (KYNA), quinolinic acid (QUIN), and picolinic acid (PIC). Picolinic acid is a natural dead-end metabolite of L-tryptophan produced via the kynurenine pathway in humans and other mammals.

The key intermediate 2-amino-3-carboxymuconate semialdehyde (ACMS) is predominantly converted to quinolinic acid (QA), a precursor for NAD⁺ biosynthesis, through spontaneous cyclization; under certain conditions, however, ACMS undergoes decarboxylation to 2-aminomuconate semialdehyde (AMS), which then spontaneously cyclizes to picolinic acid.

The enzyme α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) is the critical regulatory switch at this branch point. ACMSD limits quinolinic acid formation by competitive production of the neuroprotective metabolite picolinic acid; therefore, decreased ACMSD activity can lead to excess quinolinic acid. ACMSD is expressed at a ratio of 1300:30:1 in kidney, liver, and brain, respectively, and its activity has been shown to be inversely proportional to the amount of NAD synthesized from tryptophan.

2.2 Relationship to Quinolinic Acid

Quinolinic acid is an N-methyl-D-aspartate (NMDA) receptor agonist, and raised levels in CSF, together with increased levels of inflammatory cytokines, have been reported in mood disorders. Increased formation of quinolinic acid may occur at the expense of kynurenic acid and neuroprotective picolinic acid. The balance between these two metabolites is therefore central to neuropathological discussions of the kynurenine pathway.

3. Traditional and Historical Use

Picolinic acid as an isolated, defined compound has no documented history of traditional use in the sense associated with herbal medicines or botanical traditions. It is a relatively recently characterized endogenous metabolite: its identification as a tryptophan catabolite and its proposal as a biologically relevant mineral transporter emerged in biochemical research from the late 20th century onward. It is an essential substance for the metabolic process present in several foods of the human diet and also a safe and inexpensive pharmaceutical with chelating activity for metal ions.

The supplemental use of picolinic acid as a chelating ligand in mineral formulations — most notably in chromium picolinate and zinc picolinate — began following biochemical research in the 1970s and 1980s. The theoretical basis, proposed by researcher Gary Evans and colleagues, was that picolinic acid found in pancreatic secretions might serve as a natural facilitator of trace mineral absorption from the gut. This particular organic molecule, picolinic acid, is a natural chelating agent and a metabolite of tryptophan produced in the liver and kidneys. The commercial development of chromium picolinate as a supplement took place primarily in the United States during the late 1980s and 1990s, following animal studies and early human trials.

4. Key Constituents and Active Compounds

4.1 Picolinic Acid as the Primary Active Entity

When used as a dietary supplement, picolinic acid itself is the primary bioactive compound. In mineral picolinate supplements, it functions as the chelating ligand. Structurally, picolinic acid is characterized by a carboxyl group at the 2-position of the pyridine ring and functions as a bidentate chelating agent, forming stable complexes with metal ions such as zinc, chromium, manganese, and iron.

4.2 Mechanisms of Chelation

Because of its unique structure, picolinic acid has a strong affinity for transition metals such as zinc, manganese, and chromium; it binds tightly to these metals, thereby neutralizing their positive charges and expediting their movement across cell membranes. Organic sources of minerals tend to absorb better as they have ligands which are more lipophilic and usually neutralize the charge of the metal, thus permitting for easier passage through the intestinal membrane.

4.3 Immunological Mechanisms

Tryptophan metabolites, including kynurenine, 3-hydroxyanthranilic acid, and picolinic acid, are key mediators of immunosuppression by cells expressing the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase (IDO). The immunological effects of picolinic acid itself appear to be complex and context-dependent: it can be both immunosuppressive (on T cells) and immunostimulatory (on macrophages).

In contrast to kynurenine and 3-hydroxyanthranilic acid, exposure of T cells with picolinic acid did not affect cell viability, whereas proliferation and metabolic activity were suppressed in a dose-dependent manner. Picolinic acid exposure induced a state of deep anergy that could not be overcome by the addition of exogenous IL-2 and inhibited Th cell polarization. Picolinic acid mediates a unique immunosuppressive program in T cells, mainly inhibiting cell cycle and metabolic activity, while leaving other effector functions intact.

On the macrophage side, there exists a pathway leading to inflammation initiated by tryptophan catabolism that communicates with the immune system through the production of picolinic acid, followed by secretion of chemokines by macrophages; these results establish the importance of picolinic acid as an activator of macrophage proinflammatory functions, providing the first evidence that this molecule can be biologically active without the need for a costimulatory agent.

4.4 Iron Chelation Mechanism

Iron chelation could be involved in macrophage inflammatory protein (MIP) induction by picolinic acid, because iron sulfate inhibited the process and the iron-chelating agent desferrioxamine induced MIP expression. Picolinic acid has been characterized as an iron chelator and is able to prevent the neurotoxic effects of quinolinate.

5. Scientific Evidence by Area of Use

5.1 Mineral Absorption: Zinc Picolinate

Picolinic acid (picolinate) is a ligand found in pancreatic secretions that appears to facilitate zinc absorption and has become a popular ingredient in some mineral formulations for this reason.

Human Clinical Evidence: The comparative absorption of zinc after oral administration of three different complexed forms was studied in 15 healthy human volunteers in a double-blind four-period crossover trial; the individuals were randomly divided into four groups, each rotating through a random sequence of oral supplementation including zinc picolinate, zinc citrate, and zinc gluconate (equivalent to 50 mg elemental zinc per day) and placebo. At the end of four weeks, hair, urine, and erythrocyte zinc levels rose significantly (p<0.005, p<0.001, and p<0.001) during zinc picolinate administration; there was no significant change in any of these parameters from zinc gluconate, zinc citrate, or placebo administration. The results of this study suggest that zinc absorption in humans can be improved by complexing zinc with picolinic acid.

Evidence Strength and Limitations: This 1987 trial (Barrie et al., Agents Actions) remains the most-cited human study on zinc picolinate absorption. It was a small crossover trial (n=15) and, critically, a more recent narrative review of clinical evidence suggests that zinc glycinate and zinc gluconate are better absorbed than other forms of zinc, partly because later studies using different assay methods have not consistently replicated the superiority of picolinate. Findings from DiSilvestro et al. indicated that among glycinate, gluconate, picolinate, and oxide, glycinate demonstrated the best absorption. Overall, the evidence for zinc picolinate's superior absorption is preliminary and not yet settled.

Contested Hypothesis — Picolinate in Pancreatic Secretions: An important mechanistic controversy concerns whether endogenous picolinate in digestive secretions physiologically aids zinc absorption. Human milk contained less than 3.7 μM picolinic acid; picolinic acid was undetectable in human infant or rat intestine or in human or rat pancreatic juice; these extremely low concentrations provide additional evidence that picolinic acid is not the low molecular weight zinc binding ligand of human milk and that it does not have an important physiological role in intestinal zinc absorption. This finding by Rebello, Lönnerdal, and Hurley (1982) remains a significant challenge to the theoretical basis for picolinate supplements as mimics of an endogenous mechanism.

5.2 Chromium Picolinate: Glucose and Lipid Metabolism

As the element chromium appears to play a role in carbohydrate and lipid metabolism, dietary supplementation with chromium picolinate has been advocated in type 2 diabetes; as chromium is not assimilated particularly well from the diet, more effective absorption is achieved through the ingestion of a picolinic acid–chromium chelate. Chromium picolinate supplementation reportedly has effects on blood glucose and lipid metabolism and body composition; in these formulations picolinic acid is generally considered the non-active ingredient that helps solubilise the metal through the formation of the chelate complex.

Although chromium picolinate has been marketed in the United States as an aid to body development for athletes and as a means of losing weight, there is insufficient evidence that it provides this effect; reviews have reported either no effect on either muscle growth or fat loss, or a small weight loss in trials longer than 12 weeks, preventing a conclusion about a positive effect of chromium supplementation.

5.3 Neuroprotection and Central Nervous System

The synthesis of picolinic acid as a product of the kynurenine pathway suggests that, similar to other KP metabolites, picolinic acid may play a role in the pathogenesis of inflammatory disorders within the CNS and possibly other organs. Picolinic acid has been reported to possess a wide range of neuroprotective, immunological, and anti-proliferative effects within the body; however, the salient physiological function of this molecule is yet to be established.

Neurons express ACMSD and can therefore divert the conversion of 3-HAA from quinolinic acid to picolinic acid, which also regulates inflammatory mediator release; picolinic acid also prevents some of the deleterious actions of quinolinic acid including its toxicity on cholinergic and dopaminergic neurons.

Treatment of human primary neurons and astrocytes with picolinic acid (PIC), quinolinic acid (QUIN), and other kynurenine metabolites at concentrations below 100 nM significantly increased intracellular NAD⁺ levels compared to non-treated cells. However, a dose-dependent decrease in intracellular NAD⁺ levels and increased extracellular LDH activity was observed in human astrocytes and neurons treated with picolinic acid at concentrations above 100 nM. This biphasic dose-response highlights the concentration-dependence of picolinic acid's neurobiological effects.

Evidence Strength: All current neuroprotective evidence for picolinic acid is derived from in vitro cell studies and animal models. There are no published human clinical trials testing picolinic acid supplementation for any neurological outcome. The current body of literature dealing with the physiological actions of picolinic acid in the CNS is limited; discrepancies and gaps in current knowledge highlight areas of research needed to promote a more complete understanding of its endogenous function in the brain.

5.4 Bone Health and Osteogenesis

Picolinic acid (PIC), a catabolite of tryptophan, induces in vitro osteogenic differentiation of mesenchymal stem cells. A 2020 study published in the Journal of Bone and Mineral Research demonstrated that picolinic acid has an anabolic effect on bone in vivo by increasing bone formation, bone mass, and bone strength in normal and ovariectomized C57BL/6 mice; activation of osteogenic pathways triggered this osteoanabolic response without any cross-related effects on mineral absorption or calciotropic hormones.

Under osteogenic conditions, human mesenchymal stem cells (MSCs) show higher levels (~50-fold) of IDO-1 activity compared with MSCs treated with growth media alone, associated with a higher production of picolinic acid without affecting serotonin levels in the supernatants of MSCs undergoing osteoblastogenesis.

Because picolinic acid was also well tolerated and absorbed with no side effects in these animal models, it is an ideal potential candidate for the treatment of osteoporosis.

Evidence Strength: Evidence for bone anabolic effects is currently limited to in vitro cell culture experiments and a single animal (mouse) study. No human clinical trials of picolinic acid for bone health have been published to date.

5.5 Antiviral Activity

Picolinic acid has demonstrated broad-spectrum antiviral activity against enveloped viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A virus (IAV), flaviviruses, herpes simplex virus, and parainfluenza virus. Mechanistic studies reveal that picolinic acid inhibits enveloped virus entry by compromising viral membrane integrity, inhibiting virus-cellular membrane fusion, and interfering with cellular endocytosis.

In pre-clinical animal models, picolinic acid exhibits promising antiviral efficacy against SARS-CoV-2 and IAV, establishing it as a broad-spectrum antiviral with promising pre-clinical efficacy against pandemic viruses.

Picolinic acid has been studied for many pharmacological applications, presenting antimicrobial, antiviral, cytotoxic, and apoptotic activities and inhibition of HIV-1 among other characteristics.

Evidence Strength: Antiviral data is restricted to in vitro cell-based assays and pre-clinical animal models. No human clinical trials have evaluated picolinic acid as an antiviral therapeutic or supplement. The 2023 study from the Indian Institute of Science involved a patent filing by the investigators, representing a potential conflict of interest.

5.6 Antimicrobial Activity Against Mycobacterium avium Complex (MAC)

Picolinic acid is a naturally occurring degradation product of tryptophan and a cheap and safe drug facilitating zinc/chromium ion absorption from the intestine; it was previously reported that picolinic acid reduced intramacrophage growth of MAC and that the effect of picolinic acid was dependent on host macrophage apoptosis. Studies have investigated in vitro and in vivo antimicrobial activities of picolinic acid in combination with the antiprotozoal drug quinacrine against intramacrophage Mycobacterium avium complex; quinacrine significantly potentiated the anti-MAC activity of picolinic acid, suggesting the usefulness of this combination in the clinical control of MAC infection.

Evidence Strength: This work is primarily in vitro and in animal models. There are no published human clinical trials of picolinic acid monotherapy or combination therapy for mycobacterial infections.

5.7 Immunomodulation and Inflammatory Disease

Picolinic acid as a macrophage secondary signal causes the activation of interferon-gamma (IFN-γ)-primed macrophages and triggers cytokine-driven inflammatory reactions; the rationale for seeking increased picolinic acid formation in chronic viral hepatitis is based on the involvement of activated macrophages in chronic viral hepatitis-associated inflammation. In a clinical study assessing picolinic acid and high-sensitivity C-reactive protein (hsCRP) in 51 patients with chronic hepatitis C infection (CHC) and 40 controls, patients with CHC showed a significant increase in plasma concentrations of picolinic acid and hsCRP (P<0.01 and P<0.05, respectively).

This study demonstrates that picolinic acid is an observable biomarker of activated tryptophan catabolism in inflammatory disease states, though it does not test picolinic acid as a therapeutic intervention.

5.8 Suicidal Behavior and Neuropsychiatric Conditions

In the cerebrospinal fluid (CSF) of suicidal patients, levels of inflammatory cytokines and the kynurenine metabolite quinolinic acid, an NMDA receptor agonist, are increased; the enzyme ACMSD limits quinolinic acid formation by competitive production of the neuroprotective metabolite picolinic acid. To test the hypothesis that deficient ACMSD activity underlies suicidal behavior, picolinic acid and quinolinic acid were measured in CSF and plasma samples from 137 patients exhibiting suicidal behavior and 71 healthy controls. This human observational study examines the picolinic acid/quinolinic acid balance as a biomarker rather than testing supplemental picolinic acid as a treatment. It provides mechanistic context but no interventional evidence.

5.9 NAD⁺ Metabolism and Niacin Synthesis

Picolinic acid is an endogenous metabolite of tryptophan that has been reported to possess a wide range of physiological actions; its effects on dietary metabolism of tryptophan to nicotinamide were investigated in growing rats. Quinolinic acid and subsequent metabolites such as nicotinamide and its catabolites were increased by administration of a diet containing 0.05% picolinic acid. A small amount of picolinic acid has a beneficial effect for conversion of tryptophan to nicotinamide, but an excessive amount of picolinic acid can be very toxic. This dose-dependent relationship with NAD⁺ metabolism is an important context for interpreting picolinic acid biology but has been studied only in animal models.

6. Body Systems and Health Areas of Association

Central Nervous System: Modulation of neuroinflammation; potential counter-balance to the neurotoxin quinolinic acid; biomarker in mood disorders, Parkinson's disease, Alzheimer's disease, and suicidal ideation.
Immune System: Dual role — suppression of T-cell proliferation and anergy induction; activation and costimulation of IFN-γ-primed macrophages; induction of macrophage-derived chemokines MIP-1α and MIP-1β.
Mineral Metabolism: Chelation and facilitation of intestinal absorption of zinc, chromium, manganese, and iron; role in zinc transport across intestinal mucosa.
Bone and Musculoskeletal System: Stimulation of osteoblastogenesis from mesenchymal stem cells; potential anabolic effects on bone mass and strength (animal data only).
Antiviral/Antimicrobial Defense: Broad-spectrum inhibition of enveloped virus entry; enhancement of macrophage-mediated killing of intracellular pathogens such as Mycobacterium avium complex.
Energy and NAD⁺ Metabolism: Regulation of the ACMSD branch point controlling flux toward NAD⁺ production vs. picolinic acid end-product formation.
Hepatic System: Elevated plasma picolinic acid is observed in chronic liver diseases including viral hepatitis and cirrhosis, indicating increased kynurenine pathway activation.

7. Dosage Forms and Reported Dosages

Picolinic acid is not commonly marketed as a standalone supplement; it is instead primarily encountered as a ligand in mineral chelate formulations. The following dosages were reported in published studies:

Zinc picolinate (human crossover trial, Barrie et al., 1987): Each group in the study rotated through four-week periods of oral supplementation including zinc picolinate, zinc citrate, and zinc gluconate, all equivalent to 50 mg elemental zinc per day.
Picolinic acid in rat diet (toxicology study, Ikeda et al., 2015): Feeding an ordinary diet containing 1% picolinic acid to growing rats caused death within a few days; toxicity of picolinic acid was higher than that of analogs such as nicotinic acid and quinolinic acid; feeding a diet containing 0.05% and 0.1% picolinic acid did not elicit decreased food intake or loss of body weight.
In vitro immunological studies: In vitro studies suggest that picolinic acid at supernatant concentrations of 1–4 mM can enhance macrophage effector function.
Bone metabolism (animal study, Duque et al., 2020): The study demonstrated anabolic bone effects in C57BL/6 mice, both normal and ovariectomized; the specific picolinic acid dose administered to mice was not reported in the abstract.

No established, validated human supplemental dose for picolinic acid in isolation has been defined in the peer-reviewed literature or by any regulatory body.

8. Safety Considerations

8.1 Animal Toxicity

Feeding an ordinary diet containing 1% picolinic acid to growing rats caused death within a few days; toxicity of picolinic acid was higher than that of analogs such as nicotinic acid and quinolinic acid. This indicates a dose-dependent toxic threshold exists in mammals, with high concentrations being lethal in animal models. Importantly, the doses used in human mineral supplementation (e.g., as the chelating ligand in zinc picolinate) deliver far smaller quantities of free picolinic acid.

8.2 Biphasic Dose-Response in Neural Tissue

Treatment of human primary neurons and astrocytes with picolinic acid at concentrations below 100 nM significantly increased intracellular NAD⁺ levels, whereas a dose-dependent decrease in intracellular NAD⁺ levels and increased LDH activity (a cytotoxicity marker) was observed at concentrations above 100 nM. This biphasic response suggests that picolinic acid may be neuroprotective at physiological concentrations but potentially cytotoxic at supraphysiological levels in neural tissue.

8.3 Iron Chelation and Mineral Balance

Picolinic acid functions as a bidentate chelating agent, forming stable complexes with metal ions such as zinc, chromium, manganese, and iron. Its iron-chelating properties carry theoretical implications for individuals with iron-deficiency states or those relying on iron bioavailability from the diet. Iron chelation is involved in the macrophage inflammatory protein induction by picolinic acid, because iron sulfate inhibited this process. High supplemental doses could theoretically alter iron homeostasis, though human studies specifically examining this interaction have not been published.

8.4 Immunological Considerations

Picolinic acid mediates a unique immunosuppressive program in T cells, mainly inhibiting cell cycle and metabolic activity. Supplementation in individuals with compromised immune function, autoimmune conditions, or those on immunosuppressive medications has not been clinically evaluated and represents a theoretical safety consideration based on in vitro immunosuppressive data.

8.5 Absence of Regulatory Monographs

As of the current literature review, picolinic acid free acid has not been assigned a formal safety monograph by the NIH Office of Dietary Supplements, EFSA, EMA, or WHO. There is no established Tolerable Upper Intake Level (UL) for picolinic acid in humans. Safety data in humans are essentially limited to the indirect evidence from zinc picolinate and chromium picolinate trials, where picolinic acid is the chelating ligand rather than the primary subject of study.

8.6 Potential Drug Interactions

Because picolinic acid chelates divalent and trivalent metal ions, supplementation could theoretically reduce the absorption of medications that depend on metal ion availability, or could interact with other metal-dependent enzymatic pathways. Picolinic acid did not affect in vitro liver activities of quinolinic acid phosphoribosyltransferase or ACMSD (a Zn-dependent enzyme) at the doses studied. However, the specific interaction profile with pharmaceutical drugs in humans has not been systematically characterized.

Summary of Evidence Quality

The scientific literature on picolinic acid spans from well-established biochemistry (its biosynthetic pathway and chelation chemistry) to highly preliminary pre-clinical data (antiviral, bone, and neuroprotective effects). For virtually all proposed health applications, the evidence hierarchy is as follows:

Established (biochemical/endogenous): Role as a dead-end metabolite of the kynurenine pathway; bidentate metal chelation chemistry; identification in biological fluids including CSF and blood.
Preliminary human evidence: One small (n=15) crossover trial of zinc picolinate showing increased tissue zinc levels; observational studies showing elevated plasma picolinic acid as a biomarker in inflammatory/infectious disease.
Animal and in vitro data only: Bone anabolic effects; antiviral activity against SARS-CoV-2 and influenza A; neuroprotective properties; macrophage immunostimulation; anti-MAC antimicrobial activity.
No human clinical trial data: All neurological, antiviral, bone health, and immunotherapy applications lack human interventional evidence.

References

Health Conditions

Health conditions that Picolinic acid may help support.

No conditions available.

Body Systems

Body systems that Picolinic acid may help support.

No body systems available.